The features and management of acquired resistance to PD1-based therapy in metastatic melanoma

Adriana Hepner; Judith M. Versluis; Roslyn Wallace; Clara Allayous; Lauren Brown; Claudia Trojaniello; Camille L. Gérard; Yanina JL Jansen; Prachi Bhave; Bart Neyns; Andrew Haydon; Olivier Michielin; Joanna Mangana; Oliver Klein; Alexander N. Shoushtari; Allison Betof Warner; Paolo A. Ascierto; Jennifer L. McQuade; Matteo S. Carlino; Lisa Zimmer; Célèste Lebbé; Douglas B. Johnson; Shahneen Sandhu; Victoria Atkinson; Christian U. Blank; Serigne Lo; Georgina V. Long; Alexander M. Menzies

doi:10.1016/j.ejca.2023.113441

Related publications

Article2017

Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma

Tuba N. Gide, James S. Wilmott, Richard A Scolyer, Georgina V. Long

Article2015

Response to anti-PD1/PDL1 therapy in patients with metastatic desmoplastic melanoma.

Zeynep Eroglu, Dae Won Kim, Douglas B. Johnson, Alain P. Algazi, Rodrigo Ramella Munhoz, Elizabeth Liniker, Ben L. Kong, Neharika Khurana, Bartosz Chmielowski, Jeffrey A. Sosman, Richard A Scolyer, Matteo S. Carlino, Michael A. Postow, Wen‐Jen Hwu, Georgina V. Long, Antoni Ribas

Preprint2023

Data from Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma

Tuba N. Gide, James S. Wilmott, Richard A Scolyer, Georgina V. Long

Preprint2023

Data from Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma

Tuba N. Gide, James S. Wilmott, Richard A Scolyer, Georgina V. Long

Article2020

Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma

Ailin Lepletier, Jason Madore, Jake S. O’Donnell, Rebecca L. Johnston, Xian-Yang Li, Elizabeth S. McDonald, Elizabeth Ahern, Anna Kuchel, Melissa Eastgate, Sally‐Ann Pearson, Domenico Mallardo, Paolo A. Ascierto, Daniela Massi, Barbara Merelli, Mario Mandalà, James S. Wilmott, Alexander M. Menzies, Charles Leduc, J. C. A. Stagg, Bertrand Routy, Georgina V. Long, Richard A Scolyer, Tobias Bald,

The features and management of acquired resistance to PD1-based therapy in metastatic melanoma

Discussion(0)

Related publications

Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma

Response to anti-PD1/PDL1 therapy in patients with metastatic desmoplastic melanoma.

Data from Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma

Data from Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma

Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma